Boston Scientific Corp. stock recently hit a 52-week low of $53.10 despite reporting robust first-quarter 2026 revenue of $5.2 billion, an 11.6% increase year-over-year. The company specializes in developing and marketing medical devices, with strong performance in its cardiovascular and electrophysiology segments. Despite market pressures, its NYSE listing provides US investors access to the innovative medtech sector.

Bernstein analyst Lance Wilkes maintained an "Outperform" rating for CVS Health (CVS) and raised its price target from $94.00 to $106.00, representing a 12.77% increase. Despite this positive analyst sentiment, GuruFocus assesses CVS as 25.3% overvalued with a GF Value™ of $77.66 against a current price of $97.34. The company has a strong GF Score™ of 81/100, but recent insider activity shows $6.2 million in share sales over the last three months, suggesting potential insider concerns about valuation.

Elevance Health shareholders re-elected three directors, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor at their annual meeting on May 13, 2026. They also rejected a proposal to limit partisan political contributions. TipRanks' AI Analyst, Spark, rates ELV as "Outperform" citing solid financial performance and reasonable valuation, despite some industry pressures.

Las Vegas Sands (LVS) has successfully completed a $1 billion public debt offering, issuing senior notes due in 2031 and 2033. The proceeds will be used to refinance existing $1 billion notes maturing in August 2026, extending the company’s debt maturity profile and covering transaction expenses. Analysts currently hold a Neutral outlook on LVS stock, citing improved operating results but also noting balance-sheet leverage and bearish technicals.

CMS Energy and Consumers Energy shareholders recently approved all director nominees and management proposals at their annual meetings. CMS Energy investors specifically approved amendments to double authorized common stock and to allow shareholders to call special meetings, while rejecting a proposal for expanded written-consent powers. An analyst maintains a Buy rating on CMS with an $82 price target, though TipRanks’ AI Analyst, Spark, rates CMS as Neutral due to stable earnings balanced by high debt and negative free cash flow.

Expeditors International reported strong first-quarter earnings, with an EPS of $1.71, exceeding consensus by $0.38, and a 4.4% rise in revenue year-over-year. Despite a consensus "Hold" rating from analysts with an average price target indicating an 11.6% downside, the company's stock has shown a 4.1% year-to-date gain and reflects investor confidence due to its market position and operational results. The logistics leader continues to navigate a recovering market, leveraging its global network and service offerings.

Tyler Technologies (TYL) shares dropped 4.6% on May 13, 2026, closing at $309.65 with an abnormal trading volume of 3.57 million shares, 6.1 times its daily average. Despite this, D.A. Davidson reiterated a Buy rating with a $460 price target, and GuruFocus indicates a fair value of $542.46, suggesting the stock may be undervalued. The company's core business of providing cloud-based software to the public sector provides stable, recurring revenue, but the stock has experienced significant volatility, declining 47.43% from its 52-week high.

South Korea is strengthening its nuclear partnership with the United States through collaborations with Southern Nuclear and NuScale Power. Korea Hydro & Nuclear Power (KHNP) signed an MOU with Southern Nuclear to enhance technical exchanges and best practices. Additionally, NuScale Power is in discussions with the South Korean government regarding potential investments in the U.S. nuclear sector, aligning with South Korea’s $350 billion investment pledge to the U.S.

Shares of Otis Worldwide Corp. (OTIS) fell 1.16% on Wednesday, closing at $73.24. This performance underperformed the broader market, as the S&P 500 Index rose 0.58% while the Dow Jones Industrial Average saw a slight decline of 0.14%. The stock is currently 27.79% below its 52-week high reached on July 15th.

Stantec reported strong Q1 2026 results, with net revenue up 9.1% to $1.7 billion and adjusted EPS increasing 14.7% to $1.33. The company achieved a record contract backlog of $9.0 billion, representing approximately 13 months of work. Stantec reaffirmed its 2026 guidance, expecting continued growth in net revenue and adjusted EPS, and declared a quarterly dividend of $0.245 per share.